Innovative advances in pediatric oncology and hematology: data of 54th Congress of the International Society of Paediatric Oncology (SIOP)-Reference-Cited by-同舟云学术

Innovative advances in pediatric oncology and hematology: data of 54th Congress of the International Society of Paediatric Oncology (SIOP)

Published:2023-02-05 Issue:4 Volume:9 Page:125-128
ISSN:2413-5496
Container-title:Russian Journal of Pediatric Hematology and Oncology
language:
Short-container-title:Ross. ž. det. gematol. onkol.

Author:

Valiev T. T.¹^ORCID

Affiliation:

1. N. N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

Abstract

The success in pediatric oncology and hematology diseases treatment opened the way to cure more than 90 % of patients with leukemias and lemphomas. The ability to share an achievements in modern paediatric oncology and hematology, to find an actual directions of development, to permit the specialists from every corner of the world to communicate and discuss the most difficult aspects in diagnosis and treatment of paediatric malignancies – the basis of the International Society of Paediatric Oncology (SIOP) work. In the current issue it is presented the thesis of reports of 54th SIOP Congress, which took place in Spain (Barcelona) from September 28 to October 1, 2022. New target drugs (blinatumomab, inotuzumab ozogamicin, dinutuximab, venetoclax, daratumumab, asciminib), cellular (CAR-T) and immune approaches for malignancies treatment, new achievements in supportive care, psychological and social aspects of medical care organization for paediatric patients with malignancies – only a few topics, that were discussed of the event.

Publisher

OOO Grafika

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference11 articles.

1. Kowalczyk J. R., Zawitkowska J., Lejman M. Long-term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC-BFM 2002 trial. Am J Hematol. 2019; 94 (11): E307–10. doi: 10.1002/ajh.25619.

2. Zdráhalová K., Štěrba J., Domanský J. The prospects for children with acute lymphoblastic leukemia of being cured has increased in the Czech Republic in the 21^st century to 90 % – outcome of the ALL IC-BFM 2002 trial. Cas Lek Cesk. 2015; 154 (2): 79–89.

3. Valiev T. T., Shervashidze M. A., Osipova I. V., Burlutskaya T. I., Popova N. A., Osmulskaya N. S., Aleskerova G. A., Sabantsev S. L., Gordeeva Z. S., Smirnov V. Yu., Poberezhnaya O. A., Yuldasheva S. N., Babich I. A., Batmanova N. A., Varfolomeeva S. R. Protocol ALL IC-BFM 2002: Outcomes of Pediatric Acute Lymphoblastic Leukemia Treatment under Multi-Center Clinical Trial. Klinicheskaya onkogematologiya. Fundamental’nyye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. 2022; 15 (2): 119–29. (In Russ.)

4. Palayullakandi A., Trehan A., Jain R. Retrospective single-center experience with OEPA / COPDAC and PET-CT based strategy for pediatric Hodgkin lymphoma in a LMIC setting. Pediatr Hematol Oncol. 2022; 39 (7): 587–99. doi: 10.1080/08880018.2022.2044418.

5. Belyaeva E. S., Susuleva N. A., Valiev T. T. The importance of intensive chemotherapy for advanced Hodgkin lymphoma in children. Russkiy meditsinskiy zhurnal. Mat’ i ditya = Russian Medical Journal of Woman and Child Health. 2020; 3 (2): 149–154. (In Russ.)